Cancer Genetics, Inc. (CGIX) Given a $6.00 Price Target at HC Wainwright

HC Wainwright set a $6.00 price target on Cancer Genetics, Inc. (NASDAQ:CGIX) in a research report report published on Tuesday morning. The firm currently has a buy rating on the medical research company’s stock.

Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Cancer Genetics from a buy rating to a hold rating in a report on Tuesday, July 18th. Dawson James began coverage on shares of Cancer Genetics in a report on Tuesday, June 27th. They issued a buy rating on the stock. Finally, Benchmark Co. began coverage on shares of Cancer Genetics in a report on Monday, June 26th. They issued a speculative buy rating and a $6.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $5.56.

Cancer Genetics (NASDAQ CGIX) opened at 3.30 on Tuesday. The firm’s 50-day moving average price is $3.73 and its 200 day moving average price is $3.46. The company’s market capitalization is $65.31 million. Cancer Genetics has a 12-month low of $1.10 and a 12-month high of $5.30.

Cancer Genetics (NASDAQ:CGIX) last released its quarterly earnings results on Monday, August 14th. The medical research company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The firm had revenue of $6.60 million for the quarter, compared to analysts’ expectations of $7.97 million. Cancer Genetics had a negative net margin of 68.48% and a negative return on equity of 48.78%. The business’s revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.28) EPS. On average, equities research analysts expect that Cancer Genetics will post ($0.87) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/cancer-genetics-inc-cgix-given-a-6-00-price-target-at-hc-wainwright.html.

In other Cancer Genetics news, Director John Pappajohn bought 86,185 shares of the firm’s stock in a transaction on Friday, August 18th. The shares were purchased at an average price of $3.24 per share, for a total transaction of $279,239.40. Following the transaction, the director now directly owns 2,608,704 shares in the company, valued at approximately $8,452,200.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders acquired 273,307 shares of company stock worth $937,180. Insiders own 21.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after buying an additional 197,619 shares during the last quarter. Northern Trust Corp raised its position in shares of Cancer Genetics by 61.0% in the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after buying an additional 12,168 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in shares of Cancer Genetics by 5,465.0% in the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after buying an additional 109,300 shares during the last quarter. KCG Holdings Inc. acquired a new position in shares of Cancer Genetics during the first quarter worth about $102,000. Finally, Renaissance Technologies LLC raised its position in shares of Cancer Genetics by 44.8% in the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after buying an additional 139,200 shares during the last quarter. Hedge funds and other institutional investors own 12.77% of the company’s stock.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply